Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study

Pediatric Blood and Cancer

Volumn 46, Issue 2, 2006, Pages 198-202

  Tebbi, C K ^a,e   Mendenhall, N ^b   London, W B ^b   Williams, J L ^b   De Alarcon, P A ^c   Chauvenet, A R ^d  

^a Tampa Children's Hospital   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Chemotherapy; Clinical staging; Early stage Hodgkin disease; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADOLESCENT; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 30444458820     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20546     Document Type: Article

References (27)

1. Hudson MM, Donaldson SS. Treatment of pediatric Hodgkin's lymphoma. Semin Hematol 1999;36:313-323.
2. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002;20:3765-3771.
3. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
4. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 1987;5:742-749.
5. Schellong G. Treatment of children and adolescents with Hodgkin's disease: The experience of the German-Austrian Paediatric Study Group. Baillieres Clin Haematol 1996;9:619-634.
6. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-259.
7. Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998;16:897-906.
8. Devita VT, Jr., Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-895.
9. Mathe G, Schwarzenberg L, Pouillart P, et al. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas. Cancer 1974;34:985-992.
10. Smithers DW. Summary of papers delivered at the Conference on Staging in Hodgkin's Disease (Ann Arbor). Cancer Res 1971;31:1869-1870.
11. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063-1083.
12. Desser RK, Golomb HM, Ultmann JE, et al. Prognostic classification of Hodgkin disease in pathologic stage III, based on anatomic considerations. Blood 1977;49:883-893.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [Ser A] 1972;135:185-198.
15. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks. Med Pediatr Oncol 1994;23:86-98.
16. Kobrinsky NL, Ramsay NK, Krivit W. Anthracycline cardiomyopathy. Pediatr Cardiol 1982;3:265-272.
17. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-1552.
18. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-550.
19. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol 2001;19:191-196.
20. Gasparini M. Anthracycline cardiotoxicity. Pediatr Hematol Oncol 1994;1:237-240.
21. Johnson GL, Moffett CB, Geil JD, et al. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediatr Hematol Oncol 1996;18:72-75.
22. Iarussi D, Indolfi P, Casal F, et al. Anthracycline-induced cardiotoxicity in children with cancer: Strategies for prevention and management. Paediatr Drugs 2005;7:67-76.
23. Anderson B. Dexrazoxane for the prevention of cardiomyopathy in anthracyclines treated pediatric cancer patients. Pediatr Blood Cancer 2005;44:584-588.
24. Pinarli FG, Oguz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2995;44:370-377.
25. Fukumi D, Uchikoba Y, Maeda M, et al. Longitudinal evaluation of anthracycline cardiotoxicity by signal-averaged electrocardiography in children with cancer. Pediatr Int 2002;44:134-140.
26. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990;11:1-20.
27. Comis RL. Bleomycin pulmonary toxicity: Current status and future directions. Semin Oncol 1992;19:64-70.